Information for Readers
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2018 Category: Cancer & Oncology Source Type: research
Table of Contents
(Source: Current Problems in Cancer)
Source: Current Problems in Cancer - January 1, 2018 Category: Cancer & Oncology Source Type: research
Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy-induced nausea and vomiting
Although chemotherapeutic agents represent a cornerstone of cancer treatment, chemotherapy-induced nausea and vomiting (CINV) affect the patients ’ quality of life and basic daily activities. Rolapitant is a novel selective neurokinin-1 receptor antagonist (NK-1 RA), which was clinically approved for prevention of CINV. The aim of the present study is to synthesize evidence about the safety and efficacy of rolapitant in combination with ot her antiemetic agents for prophylaxis against CINV. We performed a web-based literature search of six authentic databases to identify eligible studies. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - December 2, 2017 Category: Cancer & Oncology Authors: Hussien Ahmed, Ali Mohamed Hammad, Abdelrahman Ibrahim Abushouk, Mohamed Zidan, Mohamed Salem, Ahmed Negida, Mohamed M. Abdel-Daim Source Type: research
Meta-analysis of safety and efficacy of rolapitant, NK-1 receptor antagonist for prevention of chemotherapy induced nausea and vomiting ☆☆
Although chemotherapeutic agents represent a cornerstone of cancer treatment, chemotherapy-induced nausea and vomiting (CINV) is one of the most disturbing hazards of cytotoxic therapy that affects the patients ‘ quality of life and basic daily activities. Rolapitant is a novel selective neurokinin-1 receptor antagonist (NK-1 RA), which was clinically approved for prevention of CINV. The aim of the present study is to synthesize evidence about the safety and efficacy of rolapitant in combination with ot her antiemetic agents for prophylaxis against CINV. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - December 2, 2017 Category: Cancer & Oncology Authors: Hussien Ahmed, Ali Mohamed Hammad, Abdelrahman Ibrahim Abushouk, Mohamed Zidan, Mohamed Salem, Ahmed Negida, Mohamed M. Abdel-Daim Source Type: research
The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis
Circulating tumor cell (CTC) is a promising candidate biomarker for detection, monitoring, and survival prediction of colorectal cancer (CRC). However, the prognostic significance of CTCs in CRC is currently under debate. Here, we performed a meta-analysis to assess the prognostic value of CTC for patients diagnosed with CRC. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 29, 2017 Category: Cancer & Oncology Authors: Yi Tan, Hao Wu Source Type: research
The significant prognostic value of circulating tumor cells in colorectal cancer: A systematic review and meta-analysis
Circulating tumor cell (CTC) is a promising candidate biomarker for detection, monitoring and survival prediction of colorectal cancer (CRC). However, the prognostic significance of CTCs in CRC is currently under debate. Here, we performed a meta-analysis to assess the prognostic value of CTC for patients diagnosed with CRC. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 29, 2017 Category: Cancer & Oncology Authors: Yi Tan, Hao Wu Source Type: research
Breast cancer and synchronous multiple myeloma as a diagnostic challenge: Case report and review of literature
We present a case report of a patient with concurrent breast cancer and multiple myeloma.A 68-year-old woman was admitted to the hospital with diagnosis of left breast cancer in first stage of the disease. In the past, she had had several episodes of thrombocytopenia, leucocytosis, and mild anaemia, which were followed by hematologist in outpatient setting. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Marcin Soko łowski, Grzegorz Mazur, Aleksandra Butrym Source Type: research
Breast cancer and synchronous multiple myeloma as a diagnostic challenge – case report and review of literature
We present a case report of a patient with concurrent breast cancer and multiple myeloma.68- year old woman was admitted to the hospital with diagnosis of left breast cancer in first stage of the disease. In the past she had had several episodes of thrombocytopenia, leucocytosis and mild anaemia, which were followed by haematologist in outpatient setting. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 21, 2017 Category: Cancer & Oncology Authors: Marcin Soko łowski, Grzegorz Mazur, Aleksandra Butrym Source Type: research
Locally advanced pancreatic cancer: An emerging entity
Pancreatic adenocarcinoma (PDAC) remains a highly fatal disease that is increasing in incidence. PDAC can be classified according to resectability status with 3 nonmetastatic groups defined: resectable, borderline resectable, and locally advanced PDAC (LAPC). Delineating these subtypes is important with the optimal treatment approach dictated by high-quality CT imaging and multidisciplinary team discussion. Patients with LAPC are thought unresectable and are therefore rarely cured. In these patients, chemotherapy remains the mainstay of treatment. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 3, 2017 Category: Cancer & Oncology Authors: Grainne M. O ′Kane, Jennifer J. Knox Source Type: research
Hepatocellular carcinoma in the era of immunotherapy
This article reviews the clinical evidence for immunotherapy in advanced hepatocellular carcinoma and presents ideas for future drug development. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 3, 2017 Category: Cancer & Oncology Authors: Hao-Wen Sim, Jennifer Knox Source Type: research
Locally advanced pancreatic cancer: An emerging entity
Pancreatic adenocarcinoma (PDAC) remains a highly fatal disease that is increasing in incidence. PDAC can be classified according to resectability status with three non-metastatic groups defined: resectable, borderline resectable and locally advanced PDAC (LAPC). Delineating these subtypes is important with the optimal treatment approach dictated by high quality CT imaging and multidisciplinary team discussion. Patients with LAPC are thought unresectable and are therefore rarely cured. In these patients chemotherapy remains the mainstay of treatment. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 3, 2017 Category: Cancer & Oncology Authors: Grainne M. O ′Kane, Jennifer J. Knox Source Type: research
Hepatocellular Carcinoma in the Era of Immunotherapy
This article reviews the clinical evidence for immunotherapy in advanced hepatocellular carcinoma and presents ideas for future drug development. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 3, 2017 Category: Cancer & Oncology Authors: Hao-Wen Sim, Jennifer Knox Source Type: research
Is the limit of 60mg of oral morphine equivalent daily dose still actual for the access to rapid onset opioids therapy?
Breakthrough cancer pain overlaps to background pain in oncology patient especially in advance stages and requires specific analgesic treatments because it has a different etiology. (Source: Current Problems in Cancer)
Source: Current Problems in Cancer - November 2, 2017 Category: Cancer & Oncology Authors: Luca Miceli, Rym Bednarova, Luigi Vetrugno, Marco Cascella, Arturo Cuomo Source Type: research
